Sign In
Buy BBIO
$65.48
+1.60 (+2.50%)
At Close: Jun 03, 2026
- In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), oral treatment with infigratinib resulted in a statistically significant and sustained increase in annualized height velocity (AHV), with a mean change from
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
04:01pm, Monday, 03'rd Jun 2024
PALO ALTO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that m
BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)
02:14pm, Monday, 03'rd Jun 2024
BridgeBio Pharma, Inc. stock has fallen by 10% since December, but recent trial data and analyst support have boosted investor enthusiasm recently. The company's primary drug candidate, Acoramidis, ha
- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortal
7 Biotech Stocks to Put on Your Breakthrough Radar
12:32pm, Monday, 27'th May 2024
For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way fir
- BridgeBio to host investor call on Wednesday, May 29, 2024 at 5:30 pm ET, with presentations from Mathew Maurer, M.D. of Columbia University Irving Medical Center, U.S. and Ahmad Masri, M.D., M.S. o
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07:30am, Wednesday, 15'th May 2024
PALO ALTO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseas
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
07:30am, Tuesday, 14'th May 2024
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseas
- In a pre-specified Cochran-Mantel-Haenszel sensitivity analysis applied to the entire intention-to-treat (ITT) population of the study (N=632), acoramidis significantly reduced all-cause mortality (
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
07:30am, Thursday, 02'nd May 2024
- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07:30am, Wednesday, 10'th Apr 2024
PALO ALTO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic dise
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07:30am, Wednesday, 20'th Mar 2024
PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic dise
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
11:53pm, Tuesday, 05'th Mar 2024
PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, tod
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
04:17pm, Monday, 04'th Mar 2024
PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, ann
